Beschreibung:
<jats:p><i>Background:</i> Gliomatosis cerebri (GC) is a diffuse infiltrating glial tumor with involvement of at least 3 cerebral lobes. There are only few data on the efficacy of initial chemotherapy in patients with GC. <i>Patients and Methods:</i> In 3 neurooncological centers, patients with newly diagnosed GC who had received procarbazine (60 mg/m<sup>2</sup>, days 8–21/56) and CCNU (110 mg/m<sup>2</sup>, day 1/56) chemotherapy (PC) as initial treatment were analyzed for progression-free survival, overall survival and toxicity. <i>Results:</i> Twelve patients (median age 46 years, range 27–72) were analyzed. The median progression-free survival and the median overall survival were 16 and 37 months. Grade 3 or 4 hematotoxicity was observed in 3 of 12 patients (25%). <i>Conclusions:</i> These data support the efficacy of PC chemotherapy in newly diagnosed GC. Initial PC chemotherapy should be considered as a treatment option and evaluated in larger clinical trials.</jats:p>